ClinicalTrials.gg
RecruitingNCT07710807PROCOGUpdated Jul 17, 2026

Transperineal Versus Transrectal Cognitive Fusion Prostate Biopsy

An interventional study of Transrectal Cognitive Fusion Prostate Biopsy and Transperineal Cognitive Fusion Prostate Biopsy in Prostate Cancer, Clinically Significant Prostate Cancer and Cognitive Fusion, sponsored by Ankara Etlik City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Prostatic Neoplasms with a site in Turkey — 22 open to participants now, 42 under way, 21 of them phase 3. Prostatic Neoplasms · Turkey.

Planned enrollment
43rd of 90
280 · median 226
Started
2026
with 12 others
No phase
40 of 111
6 open now
Primary completion
2026-12
later than 19 of 41 live
Registered
107th of 111
by date
Lead sponsor
4 of 111
Ankara Etlik City Hospital

Among the 111 studies in Prostatic Neoplasms with a site in Turkey, this one is the 43rd largest by planned enrollment of the 90 interventional ones that give a count, is one of 13 that started in 2026, is one of 40 with no phase, reaches primary completion later than 19 of the 41 other live ones, and was the 107th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

22 of the 111 studies in Prostatic Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 50 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Prostatic Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This prospective randomized controlled trial aims to compare transperineal and transrectal cognitive fusion prostate biopsy techniques in patients with suspicious prostate lesions detected by multiparametric magnetic resonance imaging (mpMRI).

Patients aged 50-75 years with PI-RADS 3-5 lesions on mpMRI and an indication for prostate biopsy will be randomly assigned in a 1:1 ratio to undergo either transperineal cognitive fusion prostate biopsy or transrectal cognitive fusion prostate biopsy.

The primary objective of this study is to evaluate whether transperineal cognitive fusion biopsy is non-inferior to transrectal cognitive fusion biopsy in detecting clinically significant prostate cancer (csPCa). Secondary objectives include comparison of overall prostate cancer detection rates, detection of Gleason Grade Group ≥2 prostate cancer, biopsy-related infectious complications, other procedure-related complications, pain scores, and procedure duration.

A total of 280 participants will be enrolled. Pathological evaluation will be performed after biopsy, and clinical outcomes and complications will be assessed during follow-up.

Read the detailed description

Prostate cancer is one of the most common malignancies among men. Multiparametric magnetic resonance imaging (mpMRI) has become an important tool for prostate cancer detection and risk stratification, particularly with the use of the Prostate Imaging Reporting and Data System (PI-RADS). Patients with PI-RADS 3-5 lesions are frequently considered candidates for targeted prostate biopsy.

Transrectal ultrasound-guided prostate biopsy has traditionally been the standard biopsy approach. However, the transrectal route may carry a risk of infectious complications due to passage through rectal mucosa and exposure to rectal flora. Transperineal prostate biopsy has gained increasing interest because it avoids transgression of the rectal mucosa and may reduce infectious complications.

Cognitive fusion biopsy is an MRI-targeted biopsy technique in which mpMRI findings are mentally correlated with real-time ultrasound images by the operator. This technique provides an accessible alternative to software-based fusion systems and can achieve accurate targeted sampling when performed by experienced clinicians.

The aim of this study is to prospectively compare transperineal and transrectal cognitive fusion prostate biopsy techniques regarding diagnostic performance and safety outcomes in patients with PI-RADS 3-5 lesions detected on mpMRI.

Eligible participants aged 50-75 years with biopsy indications will be randomized using a computer-generated stratified block randomization method. Randomization will be stratified according to PI-RADS category (3, 4, or 5) and age group (\<60 years and ≥60 years).

Participants will undergo either transperineal or transrectal cognitive fusion prostate biopsy according to their assigned study group. Systematic biopsy cores and targeted biopsy cores will be obtained according to the institutional protocol.

The primary endpoint is the detection rate of clinically significant prostate cancer, defined as Gleason Grade Group ≥2 (ISUP Grade Group ≥2) prostate cancer. The primary analysis will evaluate non-inferiority of transperineal biopsy compared with transrectal biopsy.

Secondary endpoints include overall prostate cancer detection rate, Gleason Grade Group ≥2 cancer detection, infectious complications (fever, urinary infection, prostatitis, sepsis), procedure-related complications (hematuria, hematospermia, urinary retention), pain assessed by visual analog scale (VAS), and procedure duration.

Participants will be followed for 30 days after biopsy for assessment of adverse events and complications.

03

Conditions studied

  • Prostate Cancer
  • Clinically Significant Prostate Cancer
  • Cognitive Fusion

Browse trials for

Keywords

  • prostate biopsy
  • Transperineal biopsy
  • Transrectal biopsy
  • Multiparametric magnetic resonance imaging
  • Prostate cancer detection
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 50-75 years.
  • Patients with PI-RADS 3, 4, or 5 lesions detected on multiparametric prostate magnetic resonance imaging (mpMRI).
  • Patients with an indication for prostate .
  • Patients who are willing to participate and provide .

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of prostate cancer.
  • Active urinary tract infection.
  • Coagulopathy or bleeding disorders preventing prostate .
  • Absence of multiparametric prostate MRI evaluation.
  • No indication for prostate biopsy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Transrectal Cognitive Fusion Prostate Biopsy

    Participants randomized to this arm will undergo transrectal cognitive fusion targeted prostate biopsy combined with systematic prostate biopsy according to the institutional protocol.

    Procedure: Transrectal Cognitive Fusion Prostate Biopsy

  • Experimental
    Transperineal Cognitive Fusion Prostate Biopsy

    Participants randomized to this arm will undergo transperineal cognitive fusion targeted prostate biopsy combined with systematic prostate biopsy according to the institutional protocol.

    Procedure: Transperineal Cognitive Fusion Prostate Biopsy

Interventions

  • ProcedureTransrectal Cognitive Fusion Prostate Biopsy

    Cognitive fusion targeted prostate biopsy performed through the transrectal approach using multiparametric MRI findings for lesion targeting, combined with systematic prostate biopsy.

  • ProcedureTransperineal Cognitive Fusion Prostate Biopsy

    Cognitive fusion targeted prostate biopsy performed through the transperineal approach using multiparametric MRI findings for lesion targeting, combined with systematic prostate biopsy.

06

What researchers measure

Primary outcomes

  1. Clinically significant prostate cancer detection rate

    Comparison of clinically significant prostate cancer (csPCa) detection rates between transperineal and transrectal cognitive fusion prostate biopsy techniques. Clinically significant prostate cancer is defined as Gleason Grade Group ≥2 (ISUP Grade Group ≥2) prostate cancer.

    Time frame: Within 4 weeks after biopsy (after final pathological evaluation)

Secondary outcomes

  1. Overall prostate cancer detection rate

    Comparison of overall prostate cancer detection rates between transperineal and transrectal cognitive fusion prostate biopsy techniques

    Time frame: Within 4 weeks after biopsy (after final pathological evaluation)

  2. Post-biopsy infectious complications

    Assessment and comparison of infectious complications including fever, urinary infection, prostatitis, and sepsis after prostate biopsy.

    Time frame: Within 30 days after biopsy

  3. Post-biopsy procedure-related complications

    Assessment and comparison of procedure-related complications including hematuria, hematospermia, urethral bleeding, and urinary retention.

    Time frame: Within 30 days after biopsy

  4. Pain score after biopsy procedure

    Assessment of patient-reported pain using the Visual Analog Scale (VAS) after biopsy.

    Time frame: Immediately after biopsy procedure

  5. Procedure duration

    Comparison of procedure duration between transperineal and transrectal cognitive fusion prostate biopsy techniques.

    Time frame: During biopsy procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 6 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710807
Responsible party
Muhammed Yusuf Aydın (DOCTOR, Ankara Etlik City Hospital) — Principal investigator
First posted
Jul 17, 2026
Start date
Jun 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

MUHAMMED Y AYDIN, Doctor
Contact
mysfa63@gmail.com
+90 554 838 4510 ext. +90
ALPER G GÖK, PROFESSOR DOCTOR
Contact
alper_gok@hotmail.com
+90 532 603 1181

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion